Clinical trial NCT01972217: Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.
Official title: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Study to Compare the Efficacy, Safety and Tolerability of Olaparib Versus Placebo When Given in Addition to Abiraterone Treatment in Patients With Metastatic Castrate-Resistant Prostate Cancer Who Have Received Prior Chemotherapy Containing Docetaxel
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Metastatic Castration-resistant Prostate Cancer
Keywords: Olaparib
castration-resistant, metastatic prostate cancer
Prior Docetaxel Chemotherapy
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
Collaborators: name: Merck Sharp & Dohme LLC
First posted: 2013-10-30
Enrollment: 158
Sex: MALE
Minimum age (years): 18
Maximum age (years): 130
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a 2-part study in patients with metastatic CRPC. Part A is an open-label safety run-in study to assess the safety, tolerability and pharmacokinetics (PK) of olaparib when given in addition to abiraterone 1000 mg once daily. Part B is a randomised, double-blind, placebo controlled comparison of the efficacy, safety and tolerability of the dose of olaparib selected from Part A when given in addition to abiraterone, versus placebo given in addition to abiraterone. Abiraterone is indicated in combination with prednisone or prednisolone for the treatment of patients with metastatic CRPC. Prednisone or prednisolone 5 mg twice daily (bid) will be administered with the abiraterone in this study.

Detailed description: This is a 2-part study in patients with metastatic CRPC. Part A is an open-label safety run-in study to assess the safety, tolerability and PK of olaparib when given in addition to abiraterone 1000 mg once daily. Part B is a randomised, double-blind, placebo-controlled comparison of the efficacy, safety and tolerability of the dose of olaparib selected from Part A when given in addition to abiraterone, versus placebo in addition to abiraterone.

Abiraterone is indicated in combination with prednisone or prednisolone for the treatment of patients with metastatic CRPC. Prednisone or prednisolone 5 mg bid will be administered with the abiraterone in this study, but throughout this protocol the treatment will be referred to simply as abiraterone.

For Part A of the study, 15 to 18 evaluable patients (Cohorts 1 and 2) are planned to be enrolled from approximately 4 sites in approximately 1 or 2 countries, and a further 12 patients may be recruited into a 3rd cohort if necessary.

For Part B of the study, approximately 140 patients who have received prior chemotherapy containing docetaxel will be randomised from approximately 40 sites in North America and Europe. Patients who have been dosed in Part A of the study may not participate in Part B.

Eligibility criteria: Inclusion Criteria:

1. Provision of signed and dated written informed consent prior to any study specific procedures.
2. Male aged 18 years and older.
3. Histologically or cytologically proven diagnosis of prostate cancer.
4. Candidate for abiraterone therapy with documented evidence of metastatic castration-resistant prostate cancer. Metastatic status is defined as at least one documented metastatic lesion on either bone scan or CT/MRI scan. Castration resistant prostate cancer is defined as rising PSA or other signs of disease progression despite treatment with androgen deprivation therapy and the presence of a castrate level of testosterone (≤50 ng/dL).
5. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 with no deterioration over the previous 2 weeks.
6. Patients must have a life expectancy ≥12 weeks.
7. Patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations, and completing PRO instruments.
8. Patients must be on a stable concomitant medication regimen, defined as no changes in medication or in dose within 2 weeks prior to start of olaparib dosing, except for bisphosphonates, denosumab and corticosteroids, which should be stable for at least 4 weeks prior to start of olaparib dosing.
9. For the randomised phase only, patients must have received chemotherapy in the form of docetaxel treatment for metastatic castration-resistant prostate cancer. Note: patients who discontinued docetaxel for toxicity reasons and without completing the full course will still be eligible to enter this study provided they received at least 2 cycles of chemotherapy.

Provide informed consent for the pharmacogenetic sampling and analyses.

Exclusion Criteria:

1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff, its agents and/or staff at the study site).
2. Previous treatment in the present study.
3. Treatment with any of the following:

   * Previous exposure to any 2nd generation anti-hormonal including abiraterone and enzalutamide
   * More than 2 prior courses of chemotherapy for metastatic prostate cancer
   * Previous use of immunotherapy or radium-223 for the treatment of metastatic prostate cancer
   * Any investigational agents or study drugs from a previous clinical study within 30 days of the first dose of study treatment;
   * Any previous exposure to a CYP17 (17α-hydroxylase/C17,20-lyase) inhibitor;
   * Substrates of CYP2D6 with a narrow therapeutic index (eg, thioridazine);
   * Potent inhibitors or inducers of CYP3A4 within 2 weeks before the first dose of study treatment (3 weeks for St John's Wort).
   * Any previous treatment with a PARP inhibitor, including olaparib.
4. With the exception of alopecia or toxicities related to the use of gonadotropinreleasing hormone agonists, any unresolved toxicities from prior therapy greater than CTCAE Grade 2 at the time of starting study treatment.
5. Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring steroids for at least 4 weeks prior to start of study treatment.
6. As judged by the Investigator, any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required.
7. Any of the following cardiac criteria:

   * Mean resting QTc \>470 msec obtained from 3 ECGs
   * Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG eg, complete left bundle branch block, third degree heart block
   * Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval.
8. Other malignancy within the last 5 years except: adequately treated non-melanoma skin cancer or other solid tumours including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for ≥5 years.
9. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:

   * Absolute neutrophil count (ANC) \<1.5 x 109/L
   * Platelet count \<100 x 109/L
   * Haemoglobin (Hb) \<100 g/L
   * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>2.5 x upper limit of normal (ULN) if no demonstrable liver metastases or \>5 x ULN in the presence of liver metastases
   * Total bilirubin \>1.5 x ULN if no liver metastases or \>3 x ULN in the presence of liver metastases (except in the case of Gilbert's disease)
   * Creatinine \>1.5 x ULN concurrent with creatinine clearance \<50 mL/min (measured or calculated by Cockcroft and Gault equation); confirmation of creatinine clearance is only required when creatinine is \>1.5 x ULN
   * If bone metastases are present and liver function is otherwise considered adequate by the Investigator then elevated alkaline phosphatase (ALP) will not exclude the patient.
10. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of olaparib or abiraterone.
11. History of hypersensitivity to active or inactive excipients of olaparib or abiraterone or drugs with a similar chemical structure or class to olaparib or abiraterone.
12. Patients with myelodysplastic syndrome/acute myeloid leukaemia.
13. Current disease or condition known to interfere with absorption, distribution, metabolism, or excretion of drugs, at the Investigator's discretion.
14. Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.
15. Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.

    Exclusion from the genetic research may be for any of the exclusion criteria specified in the main study or any of the following:
16. Previous allogeneic bone marrow transplant.
17. Non-leukocyte depleted whole blood transfusion within 120 days of the date of the pharmacogenetic sample collection.

Primary outcomes:
measure: Part A: Percentage of Patients Experiencing Adverse Events (AEs)
timeFrame: Cohort 1 and 2: From baseline in Part A (Day 1 for each cohort) up to 30 days following last dose of study treatment.
measure: Part A: Number of Patients With Dose Limiting Toxicities (DLTs)
timeFrame: From Day 1 for Cohort 1 and from Day 4 for Cohort 2 up to 14 days treatment with olaparib + abiraterone for 3 patients.
measure: Part B: Median Radiological Progression-Free Survival (rPFS) Time
timeFrame: From baseline, every 12 weeks up to Week 72, then every 24 weeks up to 24 months.
measure: Part B: Percentage of Patients With Progression Events or Death (rPFS)
timeFrame: From baseline, every 12 weeks up to Week 72, then every 24 weeks up to 24 months.
Secondary outcomes:
measure: Part A Pharmacokinetics (PK): Olaparib Maximum Plasma Concentration at Steady State (Cmax,ss)
timeFrame: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
measure: Part A PK: Abiraterone Cmax,ss
timeFrame: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
measure: Part A PK Analysis: Olaparib Time to Reach Maximum Plasma Concentration at Steady State (Tmax,ss)
timeFrame: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
measure: Part A PK: Abiraterone Tmax,ss
timeFrame: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
measure: Part A PK Analysis: Olaparib Minimum Plasma Concentration at Steady State (Cmin,ss)
timeFrame: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
measure: Part A PK: Abiraterone Cmin,ss
timeFrame: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
measure: Part A PK Analysis: Olaparib Area Under the Plasma Concentration-Time Curve at Steady State (AUCss)
timeFrame: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
measure: Part A PK: Abiraterone AUCss
timeFrame: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
measure: Part B: Percentage of Patients Experiencing AEs
timeFrame: From first dose of study treatment following randomisation in Part B up to 30 days following last dose of study treatment (up to approximately 3 years).
measure: Part B: Median Best Percentage Change From Baseline in Prostate Specific Antigen (PSA) Levels
timeFrame: From baseline, then every 4 weeks up to Week 52, and then every 12 weeks.
measure: Part B: Percentage of Patients With PSA Responses
timeFrame: From baseline, then every 4 weeks up to Week 24, and then every 12 weeks.
measure: Part B: Median Best Percentage Change From Baseline in Circulating Tumour Cell (CTC) Level
timeFrame: From baseline, then every 4 weeks up to Week 24, and then every 12 weeks.
measure: Part B: Percentage of Patients With at Least One Objective Response (Objective Response Rate [ORR])
timeFrame: From baseline, then every 4 weeks up to Week 52, and then every 12 weeks.
measure: Median Time to First Subsequent Therapy (TFST) and Median Time to Second Subsequent Therapy (TSST)
timeFrame: From randomisation until analysis cut-off date (up to approximately 3 years).
measure: Part B: Median Overall Survival (OS)
timeFrame: From baseline, every 12 weeks up to Week 72, then every 24 weeks up to 24 months.
measure: Part B: Median Time to Second Progression or Death (PFS2)
timeFrame: From randomisation until analysis cut-off date (up to approximately 3 years).
Other outcomes:
Locations:
city: San Diego
country: United States
facility: Research Site
state: California
city: Lake Success
country: United States
facility: Research Site
state: New York
city: Edegem
country: Belgium
facility: Research Site
city: Liège
country: Belgium
facility: Research Site
city: Wilrijk
country: Belgium
facility: Research Site
city: London
country: Canada
facility: Research Site
state: Ontario
city: Greenfield Park
country: Canada
facility: Research Site
state: Quebec
city: Montreal
country: Canada
facility: Research Site
state: Quebec
city: Brno
country: Czechia
facility: Research Site
city: Brno
country: Czechia
facility: Research Site
city: Liberec
country: Czechia
facility: Research Site
city: Angers
country: France
facility: Research Site
city: Dijon
country: France
facility: Research Site
city: LYON cedex 08
country: France
facility: Research Site
city: Lecce
country: Italy
facility: Research Site
city: Mirano
country: Italy
facility: Research Site
city: Napoli
country: Italy
facility: Research Site
city: Parma
country: Italy
facility: Research Site
city: Pisa
country: Italy
facility: Research Site
city: Arnhem
country: Netherlands
facility: Research Site
city: Maastricht
country: Netherlands
facility: Research Site
city: Nijmegen
country: Netherlands
facility: Research Site
city: Gdańsk
country: Poland
facility: Research Site
city: Warszawa
country: Poland
facility: Research Site
city: Ivanovo
country: Russian Federation
facility: Research Site
city: Moscow
country: Russian Federation
facility: Research Site
city: Moscow
country: Russian Federation
facility: Research Site
city: St. Petersburg
country: Russian Federation
facility: Research Site
city: Badalona
country: Spain
facility: Research Site
city: Córdoba
country: Spain
facility: Research Site
city: Gerona
country: Spain
facility: Research Site
city: L'Hospitalet de Llobregat
country: Spain
facility: Research Site
city: Madrid
country: Spain
facility: Research Site
city: Palma de Mallorca
country: Spain
facility: Research Site
city: Valencia
country: Spain
facility: Research Site
city: Cardiff
country: United Kingdom
facility: Research Site
city: Exeter
country: United Kingdom
facility: Research Site
city: Manchester
country: United Kingdom
facility: Research Site
city: Plymouth
country: United Kingdom
facility: Research Site
city: Torquay
country: United Kingdom
facility: Research Site
city: Westcliff-on-Sea
country: United Kingdom
facility: Research Site
Study officials:
References:
citation: Clarke N, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Flechon A, Redfern C, Goessl C, Burgents J, Kozarski R, Hodgson D, Learoyd M, Saad F. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2018 Jul;19(7):975-986. doi: 10.1016/S1470-2045(18)30365-6. Epub 2018 Jun 4.
citation: Saad F, Thiery-Vuillemin A, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Flechon A, Redfern C, Kang J, Burgents J, Gresty C, Degboe A, Clarke NW. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2022 Oct;23(10):1297-1307. doi: 10.1016/S1470-2045(22)00498-3. Epub 2022 Sep 2.